摘要
目的分析克罗恩病(CD)患者的英夫利昔单抗(IFX)血药浓度及抗英夫利昔单抗抗体(ATI)水平的监测结果,为IFX的临床合理应用提供参考。方法对北京大学深圳医院2018年1—12月共37例接受IFX治疗并监测的CD患者数据进行回顾性分析。结果共67例次监测结果显示IFX的平均谷浓度为(5.59±1.26)μg/ml,ATI阳性患者的IFX谷浓度水平明显低于ATI阴性患者(P=0.029),机体白蛋白(ALB)降低和C反应蛋白(CRP)升高均可导致IFX谷浓度偏低。结论 IFX血药浓度个体化差异大,易受较多因素影响,应定期规律监测IFX血药浓度和ATI情况,根据监测结果制订个体化治疗方案,提高药物疗效。
Objective To provide a basis for the rational use of infliximab(IFX)by analyzing the blood concentration of infliximab(IFX)and anti-infliximab antibody(ATI)in patients with Crohn’s disease(CD).Methods A retrospective analysis was conducted on 37 patients with CD who underwent IFX treatment and were monitored from January to December 2018 in Peking University Shenzhen Hospital.Results The level of IFX in ATI-positive patients was significantly lower than that in ATI-negative patients(P=0.029),and decreased albumin(ALB)and elevated C-reactive protein(CRP)resulted in low IFX concentrations.Conclusion The individualized difference of blood concentration of IFX is large and susceptible to many factors.IFX blood concentration and ATI should be monitored regularly,and individualized treatment plans should be formulated according to the monitoring results to improve the efficacy of the drug.
作者
陈佳音
张耀东
王立军
CHEN Jia-Yin;ZHANG Yao-Dong;WANG Li-Jun(Peking University Shenzhen Hospital,Shenzhen 518000,China)
出处
《中国药物经济学》
2019年第6期51-53,57,共4页
China Journal of Pharmaceutical Economics
关键词
英夫利昔单抗
血药浓度监测
克罗恩病
Infliximab
Blood concentration monitoring
Crohn’s disease
